22. 4月 2019 - 8:00
それを共有します:

World Congress on Advancements in Tuberculosis and Lung Diseases (CSE) | | 月曜日, 22. 4月 2019

 World Congress on Advancements in Tuberculosis and Lung Diseases
About The Conference
Conference Series llc LTD heartily invites across the globe to attend World Congress on Advancements in Tuberculosis and lung diseases scheduled during April 22-23, 2019 Tokyo, Japan. This incorporates provoke keynote introductions, Oral talks, Poster introductions and Exhibitions.
Conference Series is an open resource platform that conducts 3000+ global events including International Conferences, Workshops, Symposia, Trade Shows, Exhibitions and Science Congresses in all the major scientific disciplines, including Clinical, Medical, and pharmaceutical, Engineering, Technology, Business Management and Life Sciences across America, Europe, The Middle East, and Asia Pacific.
Why To Attend
Tuberculosis 2019 is one of the important microbiological colloquium that brings together clinicians, researchers, and also other public health planners/association committees or professionals. Tuberculosis research is at its apex, predominantly as discoveries in the lab are being executed into treatments in a more targeted and accurate manner.
Tuberculosis 2019 renders two days of robust deliberation on the methods and strategies which are allied to the symptoms and management of Tuberculosis as well as traverse new ideas and concepts on the global scale to diminish the airborne diseases and also the topics include tuberculosis complications, treatment and therapies for tuberculosis, Advancement in Treatment and Diagnosis, Present framework and risk factor of Tuberculosis, Clinical trials in respiratory diseases, TB Education and Research. The conference invites TB and respiratory surgeons, TB associated camps and all the noteworthy researchers and experts in the field of Infectious Diseases. The conference welcomes the researchers and delegates from TB Health care sectors to the conference for the participation. It aims to expose current and future trends, new techniques, epidemiology’s among peers, speakers, learning space for young researchers, and workshops.
TARGET AUDIENCE
Leading Scientists Practitioners Health Care Experts Treatment Providers Public Health Professionals and Community Health Educators Research Scholars and Students Tuberculosis and Lung Diseases Associations Lung cancer Surgeons University Professors Lung & respiratory associations and their members Tuberculosis Societies and their members Founders and Employees of health-related companies Experts of TB control Program Medicine, TB and Pharma institutes Pharma Companies
Sessions/Tracks
Track 01: Mycobacterial Infections
Tuberculosis is a chronic inflammatory infectious disease which is caused by the bacteria, Mycobacterium tuberculosis. Tuberculosis generally affects the lungs, but it can also affect other parts of the body. Most infections are asymptomatic, known as latent tuberculosis. About 10% of latent infections progress to active disease, if left untreated, mostly kills about half of those infected. Symptoms of active TB are chronic cough with blood-containing sputum, night sweats, one weight loss and fever. Infection of other organs can cause a wide range of symptoms including bones and joint pains, chest pain, neurological disorders and chronic pulmonary or respiratory distress etc.

Track 02: Epidemiology of the Disease
Tuberculosis epidemiology is the field of science that is concerned with the study of health and disease within populations and the various circumstances that lead to these conditions, with a goal of preventing the spread of disease. One-third of the world's population has been infected with M. tuberculosis. 13.7 million Chronic active cases, were reported by 2007 and 8.8 million new cases were roughly calculated in 2010 and 1.45 million deaths, are frequently noted in developing countries. Out of these, 0.35 million deaths occur in those co-infected with HIV. In 2012, around 450,000 people developed MDR-TB. TB incidence varies with age. In Africa, TB chiefly affects adolescents and young adults. However, in United States, TB has gone from high to low incidence, where TB is mainly a disease of older people, or of the immunosuppressed.
Since 1985, Lung cancer has been the most quotidian cancer in the globe. Worldwide, lung cancer, new cancer diagnosis and cancer fatalities. COPD is the fourth leading cause of death in the United States and is related to age. Lung cancer intensifies with age, especially after age 60. The average age of patients diagnosed with lung cancer is 70 years.

Track 03: Genetics of M. tuberculosis
In 1998, the genome of the H37Rv strain was published. The size of the genome is 4 million base pairs, and has 3959 genes, out of these 40% of genes have their function characterised and another 44% which are hypothesized with possible functions. Six pseudo genes are present within the genome.
Genome contains 250 genes involved in fatty acid metabolism, with 39 of these involved in the polypeptide metabolism generating the waxy coat. Such vast numbers of conserved genes show the revolutionary importance of the waxy coating to pathogen survival.M. tuberculosis can grow on the lipid cholesterol as a sole source of carbon, as genes involved in the cholesterol use pathways that have been important during various stages of the infection with tuberculosis. 10% of the coding genes are taken up by the amino acids that encode acidic, glycine-rich proteins. These proteins have a conserved N-terminal motif, deletion of which leads to impaired growth in granulomas and macrophages.

Track 04: Pulmonary Diseases and Therapeutics
Advanced diagnostic techniques such as X-ray and echocardiography is used to diagnose lung diseases and lung function tests is another test to determine lung cancer disease. This is a medical process involving the pleural cavity and other thoracic internal examination, biopsy and resection of the disease or mass. Thoracoscopy may be sedation under general anesthesia or local anesthesia. Surgical biopsy is a better way to diagnose lung cancer standards. Must wear appropriate masks & monitor exposure and in some working environments it is important to take precautions. Chronic obstructive pulmonary disease is a gradual process that causes difficulties in the death of respiratory failure or its associated lung disease and is the process of stopping smoking.

Track 05: Lung Infection
A Lung infection affects lungs, either in the larger airways or in the smaller air sacs. There is a build-up of pus and fluid, and the airways become swollen, making it difficult to breathe. Chest infections can affect the people of all ages. Young children and the elderly are most at risk, as well as people who are ill and smokers. A chest infection can be serious for these people.

Track 6: Vaccines & Immunization
As of 2011, the only available vaccine is Bacillus Calmette-Guérin , is a vaccine for tuberculosis disease. Many people have been BCG-vaccinated. BCG is primarily used as a vaccine in many countries which is a high aid for preventing TB as childhood tuberculous meningitis and miliary disease. Tuberculosis can be treated by taking several drugs for 6 to 9 months. There are 10 drugs which are presently approved by FDA for treating TB. Out of the approved drugs, the first-line anti-TB agents that form the basis of treatment regimens include: isoniazid, pyrazinamide rifampin, ethambutol, streptomycin. Once the TB patient is known to be fully susceptible to ethambutol or streptomycin, it can be discontinued.
Directly observed therapy (DOT) is mainly recommended for all the patients. With DOT treatment, patients with the above regimens can shift to 2 to 3 times per week dosage after an initial 2 weeks of daily dosing. Patients on twice-weekly dosing should not miss any doses. Require daily therapy for patients on self-administered medication.

Track 7: TB Clinical Trials
Clinical trials are concerned with diagnosis and treatment of the disease. The development of drug-resistant TB (XDR-TB) and multidrug-resistant TB (MDR-TB) are extensively a rising global health problem. A recent advance in the progress of new drugs & regimens provides hope that may be well effective, tolerated and shorter-duration treatment for tuberculosis will become available. During clinical trials they promote research within local TB control programs through association on clinical research of importance to public health settings, and to provide a platform for international collective research of consequence to both domestic and universal TB control.
Rapid urine-based screening for Tuberculosis in hospitalised patients in Africa to reduce AIDS-related mortality. Thibela TB is the mass screening and treatment plan in mining communities, The ZAMSTAR trial is the community TB testing and counselling, Diabetes correlated with increased risk of TB in the United Kingdom are some of the latest clinical trials or the projects going-on to reduce the risk of Tuberculosis.

Track 8: Resistance to TB Drugs
Multidrug-resistant TB (MDR-TB) begins when an antibiotic fails to eradicate all the bacteria that it targets, with the surviving bacteria producing resistance to that antibiotic and usually others at the same time. Primary Multidrug resistant, MDR-TB occurs in patients who was not earlier been infected with TB but who became infected with a strain which is resistant to the treatment. Acquired multidrug resistance for TB occurs in patients during treatment with a drug regimen that is not competent of killing the particular strain of TB with which they have been infected. MDR-TB requires treatment with second-line drugs, often four or more anti-TB drugs for a minimum of 6 months and a maximum for 18–24 months, if rifampin resistance has been identified in the specific strain of TB with which the patient has been infected. Under ideal program conditions, MDR-TB cure rates can approach 70%. In general, second-line drugs are less effective, more toxic and much more expensive than first-line drugs.

Track 9: TB Co-Infections
TB and HIV co-infection is that where people have both, either latent or active TB disease and also HIV infection. In addition to HIV infection is speeding up the progress from latent TB infection to active TB disease, in accordance TB bacteria also enhance the progression of HIV infection. Than many other opportunistic infections, TB occurs earlier in the course of HIV infection. In co-infected individuals, the risk of death is also twice that of HIV infected individuals without TB, even when antiretroviral therapy and CD4 cell count are taken into account. The provision of anti TB drug therapy and HIV antiretroviral treatment at the same time involves a number of potential difficulties including: A high pill burden, Drug – drug interactions, Cumulative drug toxicities.
TB and Diabetes co-infection: Poorly controlled diabetes can lead to numerous complications, including neuropathy, vascular disease, and increased susceptibility to infection. Diabetes may also lead to increased susceptibility to the disease via multiple mechanisms that are caused by M. tuberculosis.
There are even other co-infections with Tuberculosis such as malaria, Typhoid fever, Dengue, hepatitis.

Track 10: TB diagnosis/ Prevention & Treatment
TB diagnosis includes microbiological studies such as sputum, alternative sampling, PCR. Immunological test involves ALS assay, transdermal patch, tuberculin skin test, mantoux skin test, heaf test, CDC classification of tuberculin reaction, BCG vaccine and tuberculin skin test, Adenosine deaminase, Nucleic acid amplification tests (NAAT), Full blood count & Interferon-? release assays.
TB prevention and control efforts depend primarily on the vaccination of infants and the detection & treatment of active cases. The World Health Organization (WHO) has achieved some success with rapid diagnostics and improved treatment regimens. US Preventive Services Task Force (USPSTF) endorses screening those who are at high risk for latent tuberculosis with either mantoux tuberculin skin tests or interferon- release assays. Prevention of TB consists of two main parts. The first part of preventing TB is to cease the transmission of tuberculosis from one person to another. This can be done firstly, by identifying people with active TB infection, and then curing them by providing the drug treatment. With the provision of proper TB therapy someone with TB will not be infectious very quickly, and so cannot spread the disease to others. The second main part of preventing TB is to prevent people with latent TB infection from developing active infectious TB disease.

Track 11: Zoonotic TB
Mycobacterium bovis is the main causative agent of bovine tuberculosis (BTB) that causes zoonotic tuberculosis (TB) in humans. Bovine TB is mostly acquired from domestic animals and their products, in which cattle’s are the major reservoir. The disease results in huge economic loss, particularly in urban and per-urban cross breed dairy cattle due to mortality, low productivity and carcass condemnation as well as trade restrictions of live animals, products and by products of animals. To prevent and control zoonotic TB, veterinary sectors must be cross sectored in controlling the disease in its animal reservoir, developing diagnostic tools for diagnosingM. bovis, strengthening surveillance systems and assessing economic impact.

Track 12: Lung Cancer
Lung cancer is currently the leading cause of cancer-related deaths in men and women in the world. Lung cancer-related trends have been mainly related to smoking over the past several decades. In 2015, the American Cancer Society handles 221,200 new cases, diagnosed as 158,040 deaths due only to lung cancer. Risk factors for lung cancer are primarily smoking and air pollution. According to the doctor's suggestion, there are no symptoms associated with the first stage of lung cancer. According to researchers' research, lung cancer mortality rate is not improved at the time of diagnosis and most lung cancer progresses to advanced stage.

Track 13: COPD
COPD is a disease involving airway inflammation and thickening. It also involves the destruction of oxygen-exchanged lung tissue. The Global Initiative for Chronic Obstructive Pulmonary Disease is described as "preventable and treatable disease, characterized by an incompletely reversible airflow limitation, which is usually progressive and is associated with an abnormal inflammatory response to harmful particles or gases. This gradual and relentless loss of lung disease is caused by emphysema caused by the destruction of the lung parenchyma. Smoking (long term smokers), chronic bronchitis, genetic factors (genes) and due to chronic inflammation and fibrosis as well as elasticity The resulting loss of small airway narrows, which leads to gradual airflow limitation, air capture, and further shortages of breathing in motion.

Track 14: Asthma & Pneumonia
Asthma is a chronic disease that makes lungs harder and affects the airways that carry air to and from the lung which leads to swelling or inflammation of the airway wall. This swelling or inflammation makes the airways extremely sensitive to irritations and increases your susceptibility to an allergic reaction. As inflammation causes the airways to become narrower, less air can pass through them, both to and from the lungs which makes difficult to breathe. Thus the patience suffers from symptoms like wheezing (a hissing sound while breathing), chest tightness, breathing problems, and coughing.

Track 15: Sarcoidosis
Sarcoidosis is the growth of tiny collections of inflammatory cells (granulomas) in different parts of your body — most commonly the lungs, lymph nodes, eyes and believe sarcoidosis results from the body's immune system responding to an unknown substance, most likely something inhaled from the is no cure for sarcoidosis, but most people do very well with little or only modest treatment. In half of cases, sarcoidosis goes away on its own. In a few cases, however, sarcoidosis may last for years and may cause organ damage. Lung symptoms--Many patients with sarcoidosis experience lung problems, which may include : persistent dry cough, shortness of breath, wheezing, chest pain.

Track 16: Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a rare, progressive and systemic disease that typically results in cystic lung destruction. It predominantly affects women, especially during childbearing years. The term sporadic LAM is used for patients with LAM not associated with tuberous sclerosis complex (TSC), while TSC-LAM refers to LAM that is associated with TSC. The condition is often misdiagnosed as asthma or chronic obstructive pulmonary disease. The first pneumothorax precedes the diagnosis of LAM in 82% of patients. The consensus clinical definition of LAM includes multiple symptoms : Fatigue, Cough, Haemoptysis, Chest pain, Chylous complications arising from lymphatic obstruction.

Track 17: Asbestosis
Asbestosis is long term inflammation and scarring of the lungs due to asbestos. Symptoms may include shortness of breath, cough, wheezing, and chest pain. Complications may include lung cancer, mesothelioma, and pulmonary heart disease. There is no specific treatment. Recommendations may include influenza vaccination, pneumococcal vaccination, oxygen therapy, and stopping smoking. Asbestosis affected about 157,000 people and resulted in 3,6000 deaths in 2015. Asbestos use has been banned in a number of countries in an effort to prevent disease.
AGENDA 2017
--------------------------------------2019 Upcoming Soon--------------------------------------
Day 1 August 21, 2017
08:30-09:30 Registrations09:30-10:00 Opening CeremonyKeynote ForumIntroduction10:00-10:40 Title: Maternal immunizations: Protects mother, fetus and newborn infantMichael Brady, Nationwide Children’s Hospital, USA10:40-11:20 Title: Cooperation in public health to fight infectious diseases in developing countries is good for theglobal economyStef Stienstra, Dutch Armed Forces / Royal Dutch Navy, NetherlandsNetworking and Refreshment Break 11:20-11:40 @ Plaza Foyer11:40- 12:20 Title: Digestive tract diseases and infectionEugénie Bergogne-Bérézin, Paris University, FranceSessions:Infectious Diseases | Immunology of Infections | Treatment for Infectious Diseases | Infectious DiseasesPrevention, Control and CureVaccines and VaccinationNeuro Infectious DiseasesSession Chair: Stef Stienstra, Royal Dutch Navy, NetherlandsSession Chair: Eugénie Bergogne-Bérézin, Paris University, France12:20-12:45 Title: Neuro sarcoidosis masquerading as Neuroborreliosis (lymes)Chandra Shekar pingili, USA12:45-13:10 Title: Student Nurses, stigma and infectious diseases: A mixed methods studyNichola Ashby, University of Nottingham, UKLunch Break 13:10-14:10 @ Plaza III14:10-14:35 Title: Roles and mechanisms of DAMPs in sepsisGuozheng Wang, University of Liverpool, Liverpool, UK14:35-15:00 Title: Varicella-zoster virus tissue tropisms and neuroattenuated vaccine developmentHua Zhu, Rutgers New Jersey Medical School, USA15:00-15:25Title: In vivo; In vitro interaction of silver nanoparticles with leucine aminopeptidase fromhuman and Plasmodium falciparumChris Whiteley, Rhodes University, Grahamstown, South Africa15:25-15:50Title: Isolation and characterization of bacterial species from patients with dental cariesand caries-free subjectsHamoud Khalid Alshaya and Khalid Sukhail G Alshammari, University of Hail, Saudi ArabiaNetworking & Refreshment Break 15:50-16:10 @ Plaza Foyer16:10-16:35Title: Baofukang suppository promotes the repair of ******* epithelial cells in responseto Candida albicansTing Li, Peking University First Hospital, China16:35-17:00 Title: Immunological non responder’s real or virtual phenomenonVivek Kattel, BPKIHS, Nepal
Day 2 August 22, 2017
PLAZA II
Sessions:Infectious Diseases | Diagnosis of Infectious DiseasesAntimicrobial | Antibiotic | Antibacterial |ResistanceTuberculosis | MalariaSession Chair: Stienstra, Dutch Armed Forces / Royal Dutch Navy, NetherlandsSession Co-chair: Chris Whiteley, Rhodes University, Grahamstown, South AfricaSession Introduction12:00-12:25Title: Analysis of blood microbiome by highly sensitive 16S Metagenomic Sequencing:A new tool for diagnosisBenjamin Lelouvier, Vaiomer, Labège, France, France12:25-12:50Title: Whole genome sequencing analysis from bacterial DNA: An attempt tomycobacterium tuberculosis complete genome sequencingIkuri Alvarez-Maya, CIATEJ, Mexico.12:50-13:15Title: In-house Real Time PCR for the diagnosis and prognostication of invasive fungalinfections in a tertiary care cancer hospitalPrashant Mule, Tata Memorial Hospital, Mumbai, IndiaLunch Break 13:15-14:15 @ Plaza III14:15-14:40 Title: Epidemiology of Hepatitis C virus in Chennai, South India during the year 2014Pavithra Saikumar, University of the Pacific, San Francis, USA14:40-15:05 Title: Dual targeting of the host-pathogen interface: Bacterial release and selective cytotoxicityValentin Trofimov, Center for Infection and Immunity of Lille, France15:05-15:30Title: Socio-economic determinants of malaria transmission risk in KwaZulu-Natal, South Africa: ABayesian inference approachOsadolor Ebhuoma, University of KwaZulu-Natal, South Africa15:30-15:55 Title: Prevalence of UMOD gene mutation among Saudi patients with Kidney FailureSaleh Ahmed Alogla, University of Hail, Saudi ArabiaNetworking & Refreshment Break 15:55-16:15 @ Plaza FoyerPoster Presentations @ 16:15-17:40ID 01Title: National Surveillance for Influenza and Influenza like illness in Qatar, January –December2015: An analysis of sentinel surveillance SystemsHamad Eid Al-Romaihi, Ministry of Public Health, Doha, QatarID 02 Title:Viral Hepatitis C serological and behavioral survey among single male laborers in QatarHamad Eid Al-Romaihi, Ministry of Public Health, Doha, QatarID 03Title: Mitochondrial DNA copy number inau1 c Egyptian patients with Hepatitis C Virus-RelatedHepatocellular CarcinomaDoaa I Hashad, clinical pathology department, Alexandria, EgyptID 04 Title: A suggestion about rapid rational conditions of CNS safety from various vaccine strategySun Shin Yi, Soonchunhyang University, Republic of KoreaID 05Title: Antimicrobial mechanism of n-hexane and dichloromethane extract of Cledodendron phlomidison Bacillus licheniformisAlok Kumar Yadav, Motilal Nehru National Institute of Technology, Allahabad, IndiaKeynote Forum09:40-10:20 Title: Human prion diseases – sporadic Jakob-Creutzfeldt diseaseMichael D. Geschwind, University of California, San Francisco, USA10:20-11:00 Title: Docking of HIV aspartic protease to gold nanoparticles: Molecular dynamics simulationsChris Whiteley, Rhodes University, Grahamstown, South AfricaNetworking and Refreshment Break 11:00-11:20 @ Plaza Foyer11:20-12:00 Title: Managing bio-threat information under the WHO international health regulations of biosecurityStef Stienstra, Dutch Armed Forces / Royal Dutch Navy, Netherlands Netherlands ID 06Title: The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles onexperimental toxoplasmosisIman Abou-El-Naga, University of Alexandria, EgyptID 07Title: Isolation and characterization of bacterial species from patients with dental caries andcaries-free subjectsHamoud Khalid Alshaya, University of Hail, Saudi ArabiaID 08 Title: Prevalence of UMOD gene mutation among Saudi patients with kidney failureSaleh Ahmed Alogla, University of Hail, Saudi ArabiaID 09Title: Evaluation of the enzyme iron superoxide dismutase (fe-sode) as a molecular marker in thediagnosis and identification of leishmania spp in the school-age population of central MexicoCatalina A. López-González, UAQ, Queretaro, MexicoID 10Title: The role of B-1 cells in reducing susceptibility to oral infection by encephalitozoon cuniculiAdriano Pereira, Master, Environmental and Experimental Pathology, Paulista University,Biomedicine course of Centro Universitario Sao Camilo, BrazilID 11Title: Immunohistochemistry approach in encephalitozoonosisAdriano Pereira, Master, Environmental and Experimental Pathology, Paulista University,Biomedicine course of Centro Universitario Sao Camilo, BrazilID 12 Title: Measles trend in the federal capital territory Nigeria, 2012-2015Ifeyinwa Aremo, NigeriaID 13Title: Isolation and characterization of bacterial species from patients with dental caries andcaries-free subjectsKhalid Sukhail G Alshammari, University of Hail, Saudi ArabiaID 14Title: An quadruplex Real-Time PCR Assays for detection of Y. pestis, F. tularensis, BrucellaYu Yang, Chinese Academy of Inspection and Quarantine, ChinaID 15Title: Detection of IgG and IgA antibodies of helicobacter pylori Seroprevalence in hepatitis Cvirus infectionFadwa M Alsharif, King Abdulaziz University, KSAID 16Title: A novel small-molecule inhibitor of influenza A virus that acts by disrupting PB2 capbindingof the viral polymeraseYuan Shuofeng, The University of Hong Kong, Hong KongID 17Title: Isolation of the monoclonal antibody with high antibody-dependent cell-mediatedcytotoxicity from the hemagglutinin head-region epitope of pandemic H1N1 Influenza VirusZi-Wei Ye, The University of Hong Kong, Hong KongID 18Title: Laboratory capacity building of molecular genotyping technology for surveillanceimprovement of measles and rubella in the country of GeorgiaNazibrola Chitadze, National Center for Disease Control and Public Health (NCDC), Tbilisi, GeorgiaID 19Title: In-house Real Time PCR for the diagnosis and prognostication of invasive fungal infectionsin a tertiary care cancer hospitalPrashant Mule, Tata Memorial Hospital, Mumbai, IndiaID 20Title: Virological and pathological characterization of an avian H1N1 influenza A virusSun-Woo Yoon, Korea Research Institute of Bioscience & Biotechnology, South KoreaID 21Title: Virological and pathological characterization of an avian H1N1 influenza A virusDae Gwin Jeong, Korea Research Institute of Bioscience & Biotechnology, South KoreaID 22 Title: Neuro Sarcoidosis Masquerading as Neuroborreliosis (Lymes)Chandra Shekar pingili, Sacred Heart and Saint Joseph Hospitals, USAID 23 Title: Immunological non responder’s as real or virtual phenomenonV Kattel, BPKIHS, NepalID 24 Title: A study of clinical profile of HIV in pediatric patientsPragya Khanna, Gujarat Medical Education and Research Society, India
Day 3 August 23, 2017
August 23, 2017PLAZA IIKeynote Forum10:00-10:40 Title: The spectrum of human prion diseasesMichael D. Geschwind, University of California, San Francisco,USA10:40-11:20 Title: Epidemiology of Hepatitis C virus in Chennai, South India during the year 2014Eugénie Bergogne-Bérézin, Paris University, FranceNetworking and Refreshment Break 11:20-11:40 @ Plaza Foyer11:40-12:20 Title: Correlation of Lyme Disease with Immune DysfunctionHarpal S. Mangat, Howard College of Medicine, USASessions:Immunology of Infections|Treatment for Infectious Diseases| Hepatitis|Antimicrobial | Antibiotic | AntibacterialResistance | Global Trends in Emerging Infectious DiseasesSession Chair: Michael D Geschwind, University of California, San Francisco, USASession Co-chair: Harpal S. Mangat, Howard College of Medicine, USASession Introduction12:20-12:45 Title: Microbiota in relation to obesity among healthy saudi femalesSteve Harakeh, King Abdulaziz University, Saudi Arabia12:45-13:15 Title: Non convulsive status epilepticus associated with ertapenem useAtul Ratra, Eisenhower Medical Center, USALunch Break 13:15-14:15 @ Plaza III14:15-15:15 Title: Genetic prion diseases & Non-prion rapidly progressive dementiasMichael D. Geschwind, University of California, San Francisco, USA15:15-15:40Title: Apple cider vinegar (ACV®) displays potent antibiotic activity directly against EscherichiaColi and Candida albicans and within in vitro monocytes exposed to microbes by inhibitinginflammatory cytokine secretionDarshna Yagnik, Middlesex University, London, UK15:40-16:05Title: Hepatitis b vaccination coverage rate and its barriers among nursing students as high riskgroup to percutaneous injuries khartoum, SudanSafaa AbdElmoneim Mohamed Fadlelmoula, SudenNetworking & Refreshment Break 16:05-16:25 @ Plaza FoyerAward Closing Ceremony
Please contact the event manager Marilyn ( ) below for:- Multiple participant discounts- Price quotations or visa invitation letters- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)- Event sponsorshipNO REFUNDS ALLOWED ON REGISTRATIONSPrices may go up any time. Service fees included in pricing.-----------------------------------------------------------------This event is brought to you by:Conference Series - NewYorkEventsListhttp://
VIO181023CRE